Business
biOasis Receives Patent Allowances for Lysosomal Storage Disease Therapeutic in Europe and Canada
biOasis Receives Patent Allowances for Lysosomal Storage Disease Therapeutic in Europe and Canada.
About this update from Bioasis Technologies Inc.
[{"type":"text","content":"\n \n \n biOasis Receives Patent Allowances for Lysosomal Storage Disease Therapeutic in Europe and Canada\n \n \nbiOasis Receives Patent Allowances for Lysosomal Storage Disease Therapeutic in Europe and Canada\n\nKey Patent Allowances Represent Major Step Toward International Exclusivity for its LSD-Therapeutic in the $2 Billion LSD Market\n\n \n VANCOUVER, BRITISH COLUMBIA--(Marketwired - Mar 27, 2014) - biOasis Technologies Inc. (TSX VENTURE:BTI)(OTCQX:BIOAF), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier, has received notices of allowance from the European and Canadian Patent offices for its patent application titled, \"Use of P97 as an Enzyme Delivery System for the Delivery of Therapeutic Lysosomal Enzymes\". \n The claims of the patent cover methods of using biOasis' brain penetrating drug delivery vector, Transcend, coupled with a lysosomal storage disease enzyme for the treatment of lysosomal storage diseases (LSD). Specifically, the Transcend-coupled enzymes claimed in the patent allowance include those that are used clinically as enzyme replacement therapies to treat lysosomal storage diseases, such as Hunter Syndrome, Hurler syndrome and others.\n \"These patent allowances in Canada and Europe complement our existing issued LSD-related U.S. patent and mark another major step towards international exclusivity in the rare disease market,\" said Rob Hutchison, CEO. \"We believe it helps validates our Transcend vector technology for treating LSD and particularly its special ability to deliver therapeutic compounds across the blood-brain barrier.\"\n biOasis' corresponding LSD therapeutic patent issued in the United States on October 1, 2013 as US 8,546,319. \n A patent allowance represents the official communications from the responsible patent authorities that an application will be issued upon final review and payment of the issuance fee. \n About Lysosomal Storage Diseases\n Lysosomal storage diseases are inherited metabolic disorders caused by a deficiency in lysosomal enzymes, of which approximately 50 have been described to date. These diseases usually affect children, many of whom die within several years of birth and some following years of dealing with symptoms of the disease that may include developmental delay, movement...